| Code | CSB-RA026119MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to MTX-463, targeting CCN4 (also known as WISP-1 or WNT1-inducible signaling pathway protein 1). CCN4 is a matricellular protein belonging to the CCN family that plays crucial roles in cell proliferation, migration, adhesion, and extracellular matrix remodeling. As a downstream effector of the Wnt/β-catenin signaling pathway, CCN4 is involved in tissue repair, wound healing, and bone formation. Dysregulated CCN4 expression has been implicated in various pathological conditions, including fibrotic diseases, osteoarthritis, cardiovascular disorders, and multiple cancers where it promotes tumor growth, angiogenesis, and metastasis.
MTX-463 is an investigational anti-CCN4 antibody designed to prevent the binding of CCN4 to its receptor, thereby inhibiting the harmful signaling pathways that promote cell proliferation, migration, inflammation, and extracellular matrix deposition in fibrotic diseases and tumor progression. This biosimilar antibody provides researchers with a cost-effective alternative for studying CCN4 function in cellular models and tissue samples, enabling investigations into fibrosis mechanisms, cancer biology, skeletal development, and inflammatory processes. The antibody supports various research applications exploring CCN4 as a potential therapeutic target and biomarker.
There are currently no reviews for this product.